Anagenics unlocks A$2.5 million from haircare IP while keeping sales upside

Anagenics turns haircare technology into immediate cash

Anagenics Limited (ASX:AN1) has converted a long-developed haircare asset into A$2.5 million in cash, completing the unconditional sale of its haircare technology and associated intellectual property, including the évolis brand assets, to YSB IP, part of York St Brands. The payment was made on 5 November, alongside A$160,000 in quarter-to-date royalties under the previous licensing arrangement.

The transaction ends Anagenics’ direct ownership of the Sale IP but preserves a financial interest in the products built around it. YSB will pay 4% of net sales each quarter for up to eight years, subject to a minimum annual payment of A$350,000. The arrangement therefore has contractual minimum payments of about A$2.8 million over its full term, although those payments sit within, rather than on top of, the A$7 million aggregate earn-out cap.

Bouf sales determine the value of the earn-out

The potential upside is tied directly to the performance of YSB products using the Sale IP. Anagenics says payments could exceed A$6 million at the current sales run-rate, but it also makes clear that this is not guaranteed: reaching the A$7 million cap depends on future sales and the agreement’s terms. Early payout provisions can apply in specified circumstances, with the remaining cap balance discounted at an annual rate of 12.5%.

That sales exposure is the next stage of a relationship that has already produced royalties from YSB’s Bouf brand. Earlier this year, the company reported that Bouf royalty growth was supporting improved cash flow, while a later update said YSB royalties received during the quarter had reached A$446,000. The new structure gives YSB responsibility for commercialisation while Anagenics continues to participate in the revenue generated by the transferred technology.

Asset sale follows first full-year profit

The cash injection arrives after a material operational turnaround. Anagenics reported a maiden full-year net profit after tax of A$308,472 for the year ended 30 June 2026, compared with a A$1.24 million loss in FY25. The company has described the IP sale as a way to strengthen its balance sheet, simplify its portfolio and create greater flexibility around capital allocation.

On the company’s own calculation, the YSB relationship could deliver more than A$10 million in aggregate value if current sales levels continue. That figure combines A$2.2 million in licence fees already received, the A$2.5 million completion payment and more than A$6 million in prospective earn-out payments. The prospective portion remains sales-dependent, and the announcement does not disclose the assets’ carrying value, tax consequences or accounting treatment of the disposal.

Non-haircare IP is the next monetisation test

Anagenics says it is continuing to assess opportunities around its BLC Cosmetics portfolio and is in active discussions to monetise its non-haircare intellectual property. That creates a clear question for the next phase: whether the haircare sale is a one-off balance-sheet event or part of a broader conversion of underused assets into cash and recurring income.